Syros Pharmaceuticals (NASDAQ: SYRS) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, valuation, dividends and earnings.

Risk & Volatility

Syros Pharmaceuticals has a beta of -3.34, suggesting that its share price is 434% less volatile than the S&P 500. Comparatively, Kamada has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.

Earnings & Valuation

This table compares Syros Pharmaceuticals and Kamada’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Syros Pharmaceuticals $1.42 million 297.00 -$48.99 million ($2.13) -7.54
Kamada $87.83 million 1.96 $1.94 million ($0.06) -76.65

Kamada has higher revenue and earnings than Syros Pharmaceuticals. Kamada is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.


This table compares Syros Pharmaceuticals and Kamada’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Syros Pharmaceuticals N/A -60.15% -54.25%
Kamada -2.24% -2.94% -2.03%

Analyst Ratings

This is a breakdown of recent ratings for Syros Pharmaceuticals and Kamada, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Syros Pharmaceuticals 0 1 5 0 2.83
Kamada 0 0 2 0 3.00

Syros Pharmaceuticals presently has a consensus price target of $24.71, indicating a potential upside of 53.86%. Kamada has a consensus price target of $8.50, indicating a potential upside of 84.78%. Given Kamada’s stronger consensus rating and higher probable upside, analysts plainly believe Kamada is more favorable than Syros Pharmaceuticals.

Institutional & Insider Ownership

59.6% of Syros Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.3% of Kamada shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.


Kamada beats Syros Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.

About Kamada

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.

Receive News & Stock Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.